

# Old Drug, New Tricks? How the BPCIA Could Increase Generic Competition for Insulins

PUBLICATIONS | LESS THAN 1 MIN READ

June 23, 2020

By: Ted Mathias and Rebecca Clegg


BioProcess Online / Biosimilar Development

*BioProcess Online* and *Biosimilar Development* published “Old Drug, New Tricks? How the BPCIA Could Increase Generic Competition for Insulins,” an article written by Axinn partner Ted Mathias and associate Rebecca Clegg.


Click to access the article on [\*BioProcess Online\*](#) and [\*Biosimilar Development\*](#).

## Related People

---



Ted Mathias



Rebecca L. Clegg

## Related Services

---

Intellectual Property

To subscribe to our publications, [click here](#).

## Featured Insights

- American Bar Association 2025 Asia-Pacific Conference  
**SPEAKING ENGAGEMENT    ANTITRUST**
- NBA Commercial Law Section 38th Annual Corporate Counsel Conference  
**SPONSORSHIP    ANTITRUST**
- GCR Live: Law Leaders Global 2025  
**SPEAKING ENGAGEMENT    ANTITRUST**
- The 32nd Annual Marketing Partner Forum  
**EVENT**
- SABA North America Corporate Counsel Retreat 2025  
**SPONSORSHIP    ANTITRUST**
- Axinn Antitrust Insight: FTC Announces Revised HSR Thresholds for 2025  
**CLIENT ALERTS    ANTITRUST**
- Four Axinn Thought Leadership Pieces Nominated for the Antitrust Writing Awards  
**AWARDS & RECOGNITIONS    ANTITRUST**

- Merger Remedies Back in Vogue Under Trump

**MEDIA MENTIONS     ANTITRUST**

- Three Takeaways from the Initial Determination at the ITC Regarding Standard Essential Patents in the 1380 Investigation

**AXINN VIEWPOINTS     INTELLECTUAL PROPERTY**

- A POSA's Motivation Is Not Required To Be the Same as the Inventor's in Evaluating Obviousness

**AXINN VIEWPOINTS     INTELLECTUAL PROPERTY**

© 2025 Axinn, Veltrop & Harkrider LLP. All Rights Reserved